Cipher Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Cipher Pharmaceuticals CEO ist Craig Mull , ernannt in Jul 2019, hat eine Amtszeit von 5.33 Jahren. besitzt direkt 3.19% der Aktien des Unternehmens, im Wert von €8.15M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.5 Jahre bzw. 3.5 Jahre.

Wichtige Informationen

Craig Mull

Geschäftsführender

US$1.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	5.3yrs
Eigentum des Geschäftsführers	3.2%
Durchschnittliche Amtszeit des Managements	2.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.5yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Craig Mull

5.3yrs

Amtszeit

US$1,045,700

Vergütung

Mr. Craig J. Mull has been Chairman of the Board of Directors at Cipher Pharmaceuticals Inc. since June 11, 2019 and its Interim Chief Executive Officer since July 29, 2019, served as its President. Mr. Mu...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Craig Mull	Interim CEO & Chairman of the Board	5.3yrs	US$1.05m	3.19% € 8.1m
Bryan Jacobs	Chief Financial Officer	2.3yrs	US$391.35k	0.020% € 49.8k
Emilio Presti	Director of Sales & Marketing	2.8yrs	keine Daten	keine Daten
Hamed Ghanei	Chief Business Officer	less than a year	keine Daten	keine Daten

2.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: PHEDas Führungsteam des Unternehmens gilt als erfahren (2.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Craig Mull	Interim CEO & Chairman of the Board	5.7yrs	US$1.05m	3.19% € 8.1m
Harold Wolkin	Lead Independent Director	8.3yrs	US$73.49k	1.43% € 3.7m
Douglas Deeth	Independent Director	1.4yrs	US$65.57k	keine Daten
Hubert Walinski	Independent Director	1.4yrs	US$62.57k	keine Daten

3.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: PHEDie Vorstandsmitglieder gelten als erfahren (3.5 Jahre durchschnittliche Amtszeit).

Cipher Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer

Cipher Pharmaceuticals Inc. Announces CFO Changes

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

Less than half of directors are independent

Independent Director recently sold €56k worth of stock

Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer

Recent updates

Investor sentiment deteriorates as stock falls 17%

Third quarter 2024 earnings released: EPS: US$0.011 (vs US$0.28 in 3Q 2023)

New major risk - Earnings quality

Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 21%

Investor sentiment improves as stock rises 18%

Cipher Pharmaceuticals Inc. Announces CFO Changes

Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 2Q 2023)

Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

Investor sentiment improves as stock rises 25%

Full year 2023 earnings released: EPS: US$0.81 (vs US$1.05 in FY 2022)

Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 24%

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.11 in 3Q 2022)

Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.

Second quarter 2023 earnings released: EPS: US$0.12 (vs US$0.085 in 2Q 2022)

Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: US$0.10 (vs US$0.083 in 1Q 2022)

Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: EPS: US$1.05 (vs US$0.29 in FY 2021)

Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023

Independent Director recently sold €56k worth of stock

Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)

Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.03 in 3Q 2021)

Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)

Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer

Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022

John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc

First quarter 2022 earnings released: EPS: US$0.08 (vs US$0.05 in 1Q 2021)

Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$0.03 (vs US$0.059 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$0.11 (vs US$0.015 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.05 (vs US$0.092 in 1Q 2020)

Cipher Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 18, 2021

Cipher Pharmaceuticals Receives Arbitration Award on Trulance

New 90-day high: €0.74

Third quarter 2020 earnings released: EPS US$0.06

Revenue beats expectations

New 90-day low: €0.59

Cipher Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day low: €0.64

Cipher Pharmaceuticals Inc. Approves the Appointment of Cathy Steiner as Director

New 90-day low: €0.69

New 90-day low - €0.71

First half earnings released

New 90-day high - €0.95

New 90-day high - €0.87

Geschäftsführer

Amtszeit

Vergütung